reports
Ligand Pharmaceuticals Inc: 1 director
A director at Ligand Pharmaceuticals Inc sold 1,804 shares at 188.310USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate$1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
LGND LIGAND PHARMACEUTICALS INCORPORATED
PLNT PLANET FITNESS INC. CLASS A
HOO HERBALIFE NUTRITION LTD.
COLL COLLEGIUM PHARMACEUTICAL INC.
AMBA AMBARELLA INC.
SKY SKYLINE CHAMPION CORPORATION
NYT NEW YORK TIMES COMPANY CLASS A
DLX DELIGNIT AG
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
NOMDN NOMAD FOODS LTD.
LILA LIBERTY LATIN AMERICA A
DUBA DRDGOLD LTD. ADS
BW BABCOCK & WILCOX ENTERPRISES
SITM SITIME
LZ LEGALZOOM.COM INC
DERM JOURNEY MEDICAL CORP
COHR COHERENT CORP
GPCR STRUCTURE THERAPEUTICS
SBGI SINCLAIR INC
FBYD FALCONS BEYOND GLOBAL INC
MRX MAREX GROUP PLC
LB LANDBRIDGE COMPANY LLC
ORKA ORUKA THERAPEUTICS INC
ECG_w EVERUS CONSTRUCTION GROUP INC.
BKTI BK TECHNOLOGIES CORP
RAL RALLIANT CORP
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidanc...
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended Sept...
Ligand to Participate in November Investor Conferences
Ligand to Participate in November Investor Conferences JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: UBS Global Healthcare Conference (Palm Beach Gardens): Management will participate in one-on-one meetings on November 10, 2025.Stifel 2025 Healthcare Conference (New York): Management will participate in a fireside chat on November 12, 2025 at 8:40 a.m. ET. Southwest IDEAS 20...
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2...
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, November 6, 2025 Time:8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference I...
Ligand to Host Investor Day on December 9, 2025
Ligand to Host Investor Day on December 9, 2025 JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a.m. to 12:00 p.m. Eastern Time at The Harvard Club. The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Scott Ples...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a novel drug-device...
Ligand to Participate in September Investor Conferences
Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand ma...
Ligand Announces Closing of Convertible Senior Notes Offering
Ligand Announces Closing of Convertible Senior Notes Offering JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible senior notes due 2030 (the “notes”). The aggregate principal amount of the notes sold in the offering was $460.0 million, which includes the purchase of an additional $60.0 million aggregate principal amount of notes by the initial purchasers pursuant to the full exercise of the initial purchasers’ option to purcha...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offe...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ligand also granted the initial purchasers of the notes (the “initial purchasers...
Ligand Announces Proposed Offering of $400 Million of Convertible Seni...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. Ligand also expec...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidan...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 (previously $6.00 - $6.25) Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended Jun...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 20...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, August 7, 2025 Time: 8:30 AM Eastern Time Conference Call:(800) 715-9871 (U.S. & Canada)(646) 307-1963 (International)Conference ID ...
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5 million milestone payment from Pelthos following the commercial launch of ZELSUVMI. “Molluscum impacts millions of people in the U.S., particularly children. We are thrilled to see th...
Ligand Announces Completion of Pelthos Therapeutics Merger with Channe...
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025 JUPITER, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced the completion o...
Ligand Announces 2025 Investor Day in New York City
Ligand Announces 2025 Investor Day in New York City JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern Time at the Harvard Club. The event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand’s Investor Relations website at . A detailed agenda, in...
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
- Jonathan Moreland
CMI CUMMINS INC.
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
OEC ORION ENGINEERED CARBONS SA
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
BRKR BRUKER CORPORATION
ASYS AMTECH SYSTEMS INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
GCBC GREENE COUNTY BANCORP INC.
WINA WINMARK CORP.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
LILA INC.
COLD LIBERTY LATIN AMERICA A
EAF AMERICOLD REALTY TRUST
ULBI GRAFTECH INTERNATIONAL
MIDD ULTRALIFE
ENR THE MIDDLEBY CORPORATION
RPAY EDGEWELL PERSONAL CARE COMPANY
PRG REPAY HOLDINGS (A)
LESL PROG HOLDINGS
GRNT INC.
ALKT LESLIES
CVRX GRANIT SKOPKE
MINM ALKAMI TECHNOLOGY
MYO INC.
FLNC CVRX
DCGO INC.
STGW MINIM
OGN INC.
PFHC MYOMO
RXO_w FLUENCE ENERGY INC
OABI DOCGO INC
WEST STAGWELL INC
SRPT ORGANON & CO
FTK PROFRAC HLDG CORP
TXO RXO INC
AESI OMNIAB INC
FINS WESTROCK COFFEE COMPANY LLC
SAREPTA THERAPEUTICS
INC.
FLOTEK INDUSTRIES INC.
MORNINGSTAR PARTNERS
L.P.
ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand’s senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions. “Ringing the Nasdaq Opening Bell marks an exciting milestone in our company’s history. Over the past few years, we have made significant prog...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.